Clinical development of Ebola virus vaccines, updating a global strategy on vaccine safety, use of a network of distributed data to monitor the safety of vaccines and case studies of communication about the safety of human papillomavirus (HPV) vaccines.
Vaccine pharmacovigilance readiness for malaria vaccine implementation, Rotavirus vaccine safety update, Dengue vaccine safety update, Interrater reliability of causality assessment for serious adverse events following immunization, Guidance on prevention and management of immunization-triggered stress responses, Harmonized approaches for the vigilance of interventions during pregnancy.
Vaccine Safety Net; Update on GACVS operations; New data on narcolepsy following the 2009 pandemic influenza vaccine; Safety of typhoid vaccines; Yellow fever mass vaccination campaigns using fractional dose.
New initiative on health product vigilance; Serious AEFI during primary infant vaccination series in South India; Global Alignment of Immunization safety
Assessment in pregnancy (GAIA) project; Dengue vaccine update; Proof-of-concept study through multi-country collaboration.
Clusters of anxiety-related reactions following immunization; Vaccine safety signals from the Uppsala Monitoring Centre database; RTS,S malaria vaccine;
Safety of HPV vaccines; Influenza A (H1N1) 2009 pandemic vaccine and narcolepsy; Safety of smallpox vaccines.
The WHO Vaccine Safety Net – improving global communication on vaccine safety; Observed rates of adverse vaccine reactions; Safety of two candidate Ebola virus vaccines; Preparing for RTS,S malaria vaccine introduction.
Preparing for dengue vaccine introduction; Preparing for malaria vaccine introduction; Safety of Ebola virus vaccines; Performance indicators for vaccine safety monitoring systems; Criteria for assessing websites with vaccine safety content; Use of vaccines during pregnancy.
Safety profile of a novel live attenuated rotavirus vaccine; Safety profile of a recombinant hepatitis E vaccine; Meningococcal A conjugate vaccine during pregnancy; Preparing for malaria vaccine introduction; Fifteen years of GACVS: challenges and opportunities.
Safety profile of Japanese encephalitis (JE) chimeric vaccine; Safety of inactivated poliovirus vaccines (IPV); Increased occurrence of febrile seizures with a seasonal influenza vaccine; Update on intussusception following rotavirus vaccine administration; Human papillomavirus vaccines safety (HPV); Vaccine safety monitoring manual.
Pentavalent vaccine in Asian countries; Zoster vaccine safety and varicella vaccine safety in immunocompromised populations; Immunization during pregnancy; Yellow Fever vaccine safety during mass immunization campaigns in sub-Saharan Africa; Safety profile of Japanese encepahlitis vaccines; Update on human papillomavirus vaccines;Update on pandemic influenza vaccine (Pandemrix®) and narcolepsy.
Thiomersal in vaccines; Aluminium adjuvants; Vaccine safety in pregnancy and lactation; Use of influenza vaccines during pregnancy; Causality assessment of Adverse Events following Immunization; Core variables for AEFI monitoring.
Safety of influenza A(H1N1)pdm09 vaccines; Rotavirus vaccines and intussusception; Vaccine safety in pregnancy and lactation; Global network for postmarketing surveillance and AEFI monitoring; Implementing the Global Vaccine Safety Blueprint.
Safety profile of meningococcal A conjugate vaccine; Causes of adverse events following immunization; Information about rates of reactions to vaccines; Developing a global strategy for enhancing vaccine safety;
Safety of pandemic A (H1N1) influenza vaccines; Febrile seizures after seasonal influenza vaccine in Australia; Porcine circoviruses and rotavirus vaccines; Live attenuated hepatitis A vaccine; Updated safety of meningococcal A conjugate vaccine; Yellow fever vaccine and breastfeeding.
Safety of pandemic A (H1N1) influenza vaccines; Review of safety profile on meningococcal A conjugate vaccine from clinical trials; Use of BCG vaccine in HIV-infected infants; Strengthening global monitoring of adverse events following immunization.
Safety of experimental malaria vaccine RTS,S/AS01; Age of administration of rotavirus vaccines; Safety of human papillomavirus vaccines; Assessing the safety of novel influenza vaccines; Safety of measles vaccine in children infected with HIV.
Safety of yellow fever vaccine; Diphtheria-tetanus-pertussis vaccine and asthma; Non-specific effects of DTP vaccine on child mortality; Pregnancy outcomes after inadvertent immunization with rubella vaccine; Mitochondrial diseases and vaccination;Thiomersal; Report from subgroups.
Guillain-Barré syndrome and vaccination; Safety of immunization in immunocompromised individuals; Safety of yellow fever vaccines; Hepatitis B vaccination and rheumatoid arthritis; Safety of live 14-14-2 Japanese encephalitis vaccine; Safety of meningococcal B vaccines; Rotavirus vaccines and Kawasaki disease; Modus operandi of the committee and additional information.
Monitoring vaccine safety; Safety of vaccine formulations; Mumps vaccine virus strain repository; Safety of BCG vaccines; Safety of human papillomavirus vaccine; Update on Menactra® and Guillain-Barré syndrome; Safety of rotavirus vaccines; Influenza vaccines: update; Modus operandi of the Committee and additional information.
Monitoring vaccine safety; Report of the WHO Expert Committee on Biological Standardization; Safety of vaccine formulations; Vaccinating adolescents and young adults: problems with coincidental pathologies and safety assessments; Safety of mumps vaccine strains; Safety of BCG vaccine in HIV-infected children; Update on Menactra® and Guillain-Barré syndrome; Pandemic influenza vaccines; Safety of Japanese encephalitis vaccination in India; Safety of pneumococcal conjugate vaccine.
Vaccine safety monitoring and the WHO Programme for International Drug Monitoring; Post-marketing surveillance of rotavirus vaccines; Safety of squalene; Immunogenic overload; Safety of pandemic influenza vaccines; Safety issues of varicella vaccines; Modus operandi of the Committee and additional information
Vaccine Safety Net; Safety issues associated with pandemic influenza vaccines; Safety of adjuvants; Rotavirus vaccine safety; Subacute sclerosing panencephalitis and measles vaccination; Chronic fatigue syndrome and hepatitis B vaccination; Conjugate meningococcal vaccine and Guillain-Barré Syndrome; Modus operandi of the Committee.
Mouse brain-derived Japanese encephalitis vaccine; Safety of SA 14-14-2 Japanese encephalitis vaccine; Isoniazid resistance of bacille Calmette-Guérin strains; International drug monitoring; Thiomersal; Safety of hexavalent vaccines; Subacute sclerosing panencephalitis and measles vaccination; National regulatory authorities planning workshops.
Safety of adjuvants; Thiomersal: neurobehavioural studies on animal models; Safety of residual cellular DNA in vaccines; Transmissible spongiform encephalopathy; Potential risk of vaccines produced on yeast; Safety of hexavalent vaccines; Yellow fever; Vaccine Safety Net.
Intranasal influenza virus vaccine; Influenzae vaccines and neurological complications; Influenza vaccination of women during pregnancy; Nonspecific effects of childhood immunization; Safety issues in the poliomyelitis eradication campaign; International reference laboratory for mumps virus isolates; Yellow fever vaccine safety; BCG immunization in HIV-positive subjects; Safety of smallpox vaccination; Switch from rubella vaccine to mumps, measles and rubella vaccine; Aluminium-containing vaccines and macrophagic myofasciitis.
Safety of thiomersal-containing vaccines; Hepatitis B vaccine and leukaemia; Hepatitis B vaccine and multiple sclerosis; Aluminium-containing vaccines and macrophagic myofasciitis; Bell palsy following intranasal vaccination; Potential adverse impact of routine vaccination on child survival